Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPRA-SWITCH: Switching sitagliptin to ipragliflozin in obese patients with type 2 diabetes mellitus
jRCTs031190022Completed
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ipragliflozin in type 2 diabetes mellitus (T2DM) and obesity, sponsored by none. Primary endpoint: Change in HbA1c from baseline. Started Jun 2019; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on jRCTs031190022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190022.